Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
79.72
Oct 30 • 3:59 PM ET Dollar change+0.92 Percentage change(1.17%)
Aftermarket Close
79.50
Aftermarket • 7:58 PM ET Dollar change-0.22 Percentage change(-0.28%)
Index
S&P 500
Market Cap
32.94B
Enterprise Value
40.50B
Income
2.62B
Sales
9.52B
Book/sh
7.60
Cash/sh
4.06
Employees
14500
IPO
Feb 01, 2013
P/E
13.11
Forward P/E
12.58
PEG
6.95
P/S
3.46
P/B
10.49
P/C
19.66
P/FCF
13.92
EV/EBITDA
9.96
EV/Sales
4.26
Quick Ratio
1.84
Current Ratio
3.08
Debt/Eq
2.93
LT Debt/Eq
2.93
Option/Short
Yes / Yes
EPS (ttm)
6.08
EPS next Y
6.34
EPS next Q
1.51
EPS this Y
-3.06%
EPS next Y
1.97%
EPS next 5Y
1.81%
EPS past 3/5Y
10.25% 11.96%
Sales past 3/5Y
5.42% 7.24%
EPS Y/Y TTM
4.54%
Sales Y/Y TTM
1.41%
EPS Q/Q
2.64%
Sales Q/Q
0.33%
Insider Own
0.23%
Insider Trans
1.24%
Inst Own
100.39%
Inst Trans
-3.95%
ROA
17.70%
ROE
64.39%
ROIC
21.12%
Gross Margin
70.22%
Oper. Margin
37.65%
Profit Margin
27.49%
SMA20
3.33%
SMA50
6.23%
SMA200
-14.76%
Trades
Shs Outstand
414.15M
Shs Float
412.28M
52W High
145.04 -45.04%
52W Low
68.77 15.92%
Volatility
2.06% 2.29%
ATR (14)
1.85
RSI (14)
60.44
Beta
0.70
Rel Volume
0.82
Avg Volume
4.99M
Volume
4,118,156
Perf Week
-1.62%
Perf Month
15.37%
Perf Quarter
3.40%
Perf Half Y
-30.17%
Perf YTD
-36.64%
Perf Year
-44.68%
Perf 3Y
-49.22%
Perf 5Y
-63.13%
Perf 10Y
64.17%
Prev Close
78.80
Price
79.72
Change %
1.17%
Consensus
Buy
Avg. Price Target
$88.00
Implied Upside
+10.4%
Analysts15incl. previous ratings
Rating Distribution5 Buy · 10 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 20, 2026Downgrade
JEF logoJJefferies
Buy → Hold$83+4.1%
Oct 16, 2026Initiated
GS logoGGoldman
Neutral$74-7.2%
Aug 06, 2026Downgrade
WWilliam Blair
Outperform → Mkt Perform
May 27, 2026Downgrade
AArgus
Buy → Hold
Apr 15, 2026Initiated
C logoCCitigroup
Buy$145+81.9%
Jan 22, 2026Downgrade
PPiper Sandler
Overweight → Neutral$135+69.3%
Dec 15, 2025Downgrade
BAC logoBBofA Securities
Buy → Neutral$135+69.3%
Dec 09, 2025Initiated
BCS logoBBarclays
Equal Weight$136+70.6%
Nov 21, 2025Initiated
KEY logoKKeyBanc Capital Markets
Sector Weight
Jul 17, 2025Downgrade
LLeerink Partners
Outperform → Market Perform$155+94.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAMELIO FRANK ADirectorMay 13 '26Buy75.396,650501,34421,458May 13 04:35 PM
Bisaro PaulDirectorMay 13 '26Buy75.882,000151,75027,862May 13 04:35 PM
MCCALLISTER MICHAEL BDirectorMay 11 '26Buy77.763,000233,27324,524May 12 07:26 PM
PECK KRISTIN CChief Executive OfficerFeb 17 '26Option Exercise41.8320,000836,600121,337Feb 17 04:22 PM
PECK KRISTIN CChief Executive OfficerFeb 17 '26Sale127.0520,0002,540,964101,337Feb 17 04:22 PM
Polzer Robert JOfficerFeb 17 '26Proposed Sale127.342,346298,742Feb 17 04:14 PM
PECK KRISTIN COfficerFeb 17 '26Proposed Sale127.0520,0002,540,964Feb 17 04:13 PM
Polzer Robert JOfficerFeb 13 '26Proposed Sale129.093,662472,728Feb 13 04:26 PM
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.
CEO & DirectorMs. Kristin C. Peck
Executive VPMs. Roxanne Lagano
Special Advisor to the CEOMr. Wetteny N. Joseph CPA
Scientific AdvisorDr. Robert J. Polzer Ph.D.
Executive VP & Chief Commercial OfficerMr. Jamie Brannan